Press Releases

Worldwide Ocaliva net sales of $249.6 million for the full year 2019, representing 40% growth over the prior year Our NDA was the first accepted by the FDA for liver fibrosis due to NASH Completed enrollment of REVERSE, our Phase 3 study evaluating OCA for the treatment of compensated cirrhosis due

NEW YORK , Feb. 18, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full year 2019 financial

NEW YORK , Jan. 29, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has completed patient enrollment in

NEW YORK , Jan. 08, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Mark Pruzanski , M.D., President and

Company submits Marketing Authorization Application to the European Medicines Agency for obeticholic acid in patients with fibrosis due to NASH FDA notifies Intercept of tentative date for previously announced Advisory Committee meeting NEW YORK , Dec.

NEW YORK , Dec. 10, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will host a NASH Commercial Day for

NEW YORK , Dec. 05, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the positive results from the interim

NEW YORK , Dec. 02, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Jason Campagna , M.D.,

NDA supported by positive interim analysis results from the Phase 3 REGENERATE study demonstrating OCA’s improvement of liver fibrosis without worsening of NASH NEW YORK , Nov. 25, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the

Treatment with OCA resulted in early and sustained improvements of commercially available noninvasive biomarker and imaging assessments of fibrosis Additional patient-reported outcomes data demonstrate that pruritus in patients treated with OCA 25 mg did not have an impact on measures of quality of